A chimeric alphavirus RNA replicon gene-based vaccine for human parainfluenza virus type 3 induces protective immunity against intranasal virus challenge (Q45213829)

From Wikidata

Jump to navigation Jump to search

scientific article published on 7 August 2006

Language	Label	Description	Also known as
English	A chimeric alphavirus RNA replicon gene-based vaccine for human parainfluenza virus type 3 induces protective immunity against intranasal virus challenge	scientific article published on 7 August 2006

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

A chimeric alphavirus RNA replicon gene-based vaccine for human parainfluenza virus type 3 induces protective immunity against intranasal virus challenge (English)

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

human parainfluenza

1 reference

based on heuristic

inferred from title

author name string

Catherine E Greer

1

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Fengmin Zhou

2

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Harold S Legg

3

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Zequn Tang

4

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Silvia Perri

5

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Barbara A Sloan

6

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Jan Zur Megede

7

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Yasushi Uematsu

8

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Michael Vajdy

9

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

John M Polo

10

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

language of work or name

0 references

publication date

7 August 2006

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

25

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

481-489

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Enhanced pulmonary pathology in cotton rats upon challenge after immunization with inactivated parainfluenza virus 3 vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Cold adaptation of parainfluenza virus type 3: Induction of three phenotypic markers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Bovine parainfluenza virus type 3 (BPIV3) fusion and hemagglutinin-neuraminidase glycoproteins make an important contribution to the restricted replication of BPIV3 in primates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Generation of a parainfluenza virus type 1 vaccine candidate by replacing the HN and F glycoproteins of the live-attenuated PIV3 cp45 vaccine virus with their PIV1 counterparts

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Expression of the surface glycoproteins of human parainfluenza virus type 3 by bovine parainfluenza virus type 3, a novel attenuated virus vaccine vector

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Comparison of the immunogenicity and efficacy of a replication-defective vaccinia virus expressing antigens of human parainfluenza virus type 3 (HPIV3) with those of a live attenuated HPIV3 vaccine candidate in rhesus monkeys passively immunized wit

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

The immunogenicity and efficacy of intranasally or parenterally administered replication-deficient vaccinia-parainfluenza virus type 3 recombinants in rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Function and immunogenicity of human parainfluenza virus 3 glycoproteins expressed by recombinant adenoviruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

The fusion and hemagglutinin-neuraminidase glycoproteins of human parainfluenza virus 3 are both required for fusion

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Chimpanzee adenovirus vaccine protects against Zaire Ebola virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Induction of simian immunodeficiency virus (SIV)-specific CTL in rhesus macaques by vaccination with modified vaccinia virus Ankara expressing SIV transgenes: influence of pre-existing anti-vector immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Rabies vaccination: comparison of neutralizing antibody responses after priming and boosting with different combinations of DNA, inactivated virus, or recombinant vaccinia virus vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Virus-based vectors for human vaccine applications

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Sindbis virus: an efficient, broad host range vector for gene expression in animal cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Stable alphavirus packaging cell lines for Sindbis virus and Semliki Forest virus-derived vectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Replicon-Helper Systems from Attenuated Venezuelan Equine Encephalitis Virus: Expression of Heterologous Genesin Vitroand Immunization against Heterologous Pathogensin Vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

A new generation of animal cell expression vectors based on the Semliki Forest virus replicon

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Apoptosis is essential for the increased efficacy of alphaviral replicase-based DNA vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Role of dendritic cell targeting in Venezuelan equine encephalitis virus pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Infection of human dendritic cells by a sindbis virus replicon vector is determined by a single amino acid substitution in the E2 glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

The complete nucleotide sequence of the JS strain of human parainfluenza virus type 3: comparison with the Wash/47885/57 prototype strain

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

A cell line that expresses a reporter gene in response to infection by Sindbis virus: a prototype for detection of positive strand RNA viruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Generation of recombinant human parainfluenza virus type 1 vaccine candidates by importation of temperature-sensitive and attenuating mutations from heterologous paramyxoviruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Antigenic variation in the hemagglutinin-neuraminidase protein of human parainfluenza type 3 virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Comparison of the safety, tolerability, and immunogenicity of a MF59-adjuvanted influenza vaccine and a non-adjuvanted influenza vaccine in non-elderly adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

PARAINFLUENZA TYPE 3 VIRUS INFECTION IN HAMSTERS: VIROLOGIC, SEROLOGIC, AND PATHOLOGIC STUDIES.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Recent advances in vaccine adjuvants: the development of MF59 emulsion and polymeric microparticles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Phase 2 evaluation of parainfluenza type 3 cold passage mutant 45 live attenuated vaccine in healthy children 6-18 months old.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Evaluation of combined live, attenuated respiratory syncytial virus and parainfluenza 3 virus vaccines in infants and young children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

A live attenuated bovine parainfluenza virus type 3 vaccine is safe, infectious, immunogenic, and phenotypically stable in infants and children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Evaluation of a live attenuated bovine parainfluenza type 3 vaccine in two- to six-month-old infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Outcome of immunization of cynomolgus monkeys with recombinant Semliki Forest virus encoding human immunodeficiency virus type 1 envelope protein and challenge with a high dose of SHIV-4 virus.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Early immunologic events in mucosal and systemic lymphoid tissues after intrarectal inoculation with simian immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Characterization of human immunodeficiency virus Gag-specific gamma interferon-expressing cells following protective mucosal immunization with alphavirus replicon particles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Alphavirus replicon particles as candidate HIV vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Vaccination with recombinant alphavirus or immune-stimulating complex antigen against respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Self-replicative RNA vaccines elicit protection against influenza A virus, respiratory syncytial virus, and a tickborne encephalitis virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Modulation of disease, T cell responses, and measles virus clearance in monkeys vaccinated with H-encoding alphavirus replicon particles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Genetic immunization against cervical carcinoma: induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Cancer immunotherapy using Sindbis virus replicon particles encoding a VP22-antigen fusion.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Human immunodeficiency virus type 1 Gag-specific vaginal immunity and protection after local immunizations with sindbis virus-based replicon particles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Evaluation of the replication and immunogenicity of recombinant human parainfluenza virus type 3 vectors expressing up to three foreign glycoproteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

A live attenuated chimeric recombinant parainfluenza virus (PIV) encoding the internal proteins of PIV type 3 and the surface glycoproteins of PIV type 1 induces complete resistance to PIV1 challenge and partial resistance to PIV3 challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Bovine parainfluenza virus type 3 (PIV3) expressing the respiratory syncytial virus (RSV) attachment and fusion proteins protects hamsters from challenge with human PIV3 and RSV.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

Attenuation of bovine parainfluenza virus type 3 in nonhuman primates and its ability to confer immunity to human parainfluenza virus type 3 challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.048

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2006.07.048

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45213829&oldid=2070155773"